PMID- 29904950
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 101
IP  - 3
DP  - 2018 Sep
TI  - Optimising management of deferasirox therapy for patients with 
      transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
PG  - 272-282
LID - 10.1111/ejh.13111 [doi]
AB  - Effective iron chelation therapy is an important part of treatment in patients 
      with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes 
      (MDS). Key strategies for optimising iron chelation therapy include ensuring good 
      adherence and preventing and managing adverse events (AEs). Good adherence to 
      iron chelation therapy with deferoxamine and deferasirox has been linked to 
      improved survival and/or reductions in complications related to iron overload; 
      however, maintaining good adherence to iron chelators can be challenging. 
      Patients with transfusion-dependent thalassaemia or lower-risk MDS showed better 
      adherence to the deferasirox film-coated tablet (FCT) formulation than to the 
      deferasirox dispersible tablet formulation in the ECLIPSE trial, reflecting in 
      part the improved palatability and convenience of deferasirox FCT. As well as 
      affecting adherence, AEs may lead to dose reduction, interruption or 
      discontinuation, resulting in suboptimal iron chelation therapy. Preventing and 
      successfully managing AEs may help limit their impact on adherence, and following 
      dosage and administration recommendations for iron chelators such as deferasirox 
      may help minimise AEs and optimise treatment in patients with 
      transfusion-dependent thalassaemia and lower-risk MDS.
CI  - (c) 2018 The Authors. European Journal of Haematology Published by John Wiley & 
      Sons Ltd.
FAU - Kattamis, Antonis
AU  - Kattamis A
AUID- ORCID: 0000-0002-5178-0655
AD  - First Department of Pediatrics, National and Kapodistrian University of Athens, 
      Athens, Greece.
FAU - Aydinok, Yesim
AU  - Aydinok Y
AD  - Department of Pediatric Hematology, Ege University Hospital, Izmir, Turkey.
FAU - Taher, Ali
AU  - Taher A
AUID- ORCID: 0000-0001-8515-2238
AD  - Naef K. Basile Cancer Institute, American University of Beirut Medical Center, 
      Beirut, Lebanon.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180727
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Iron Chelating Agents)
RN  - V8G4MOF2V9 (Deferasirox)
SB  - IM
MH  - Blood Transfusion/methods
MH  - Chelation Therapy
MH  - Deferasirox/administration & dosage/adverse effects/*therapeutic use
MH  - Disease Management
MH  - Humans
MH  - Iron Chelating Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Iron Overload/*drug therapy/*etiology
MH  - Liver Function Tests
MH  - Medication Adherence
MH  - Myelodysplastic Syndromes/*complications/diagnosis/therapy
MH  - Thalassemia/*complications/diagnosis/therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - deferasirox
OT  - iron overload
OT  - myelodysplastic syndromes
OT  - thalassaemia
OT  - therapy
EDAT- 2018/06/16 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/06/16 06:00
PHST- 2018/06/11 00:00 [accepted]
PHST- 2018/06/16 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/06/16 06:00 [entrez]
AID - 10.1111/ejh.13111 [doi]
PST - ppublish
SO  - Eur J Haematol. 2018 Sep;101(3):272-282. doi: 10.1111/ejh.13111. Epub 2018 Jul 
      27.